Feedback
Settings

Settings

Goto Application

280,900 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,090
1.20260015650Rapid Extraction of Nucleic Acids from Clinical Samples for Downstream Applications
US - 15.01.2026
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No 19253477 Applicant The Regents of the University of California Inventor Deborah Anne Dean

Disclosed herein are novel methods and compositions for rapidly extracting and amplifying nucleic acids from a sample where the sample is combined with an extraction reagent comprising a reducing agent to form a mixture and incubating said mixture at ambient temperature for a period of time not exceeding 30 minutes to generate a nucleic acid extract. In certain embodiments of the method, the nucleic acid extract is subjected to a nucleic acid amplification reaction. In certain aspects, oligonucleotide primers specific for nucleic acids of Chlamydia species and/or Neisseria species are added prior to initiating the amplification reaction.

2.WO/2026/014409METHOD FOR PRODUCING ALKYLATED URACIL DERIVATIVE
WO - 15.01.2026
Int.Class C07D 405/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/JP2025/024319 Applicant AGC INC. Inventor NOMURA, Yoshitaka
Provided is a method for synthesizing an N1-alkylated uracil derivative from a uracil derivative by one step, comprising a step for synthesizing, from a compound represented by general formula (1), a compound represented by general formula (2) by an alkylation reaction in the presence of a TMS group-containing compound. [In the formulas, is a hydrogen atom, an alkali metal atom, or -P(=O)(OR11)(OR12) (where R11 and R12 each independently represent a monovalent cation, an alkyl group which may have a substituent, or an acyl group); the ring A represents a 5- to 8-membered ring; when R1 is other than a hydrogen atom, the ring A is substituted with at least one hydroxy group; R2 is a group including a structure represented by formula (r2); and R3 represents a group including a structure represented by formula (r3) (where R31 is an alkyl group).]
3.WO/2026/0143655’ CAP ANALOG
WO - 15.01.2026
Int.Class C07H 19/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
 Appl.No PCT/JP2025/024109 Applicant NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM Inventor ABE, Hiroshi
Provided is a technique for more easily obtaining a 5’ capped polynucleotide which is purified and exhibits high translation activity. The 5' cap analog is characterized in that a hydroxy group at the 2’ and/or 3’ position of ribose contained in 7-methylguanylic acid is substituted with a non-photodegradable hydrophobic protecting group.
4.20260013535STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS
US - 15.01.2026
Int.Class A23L 27/30
AHUMAN NECESSITIES
23FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; PREPARATION, TREATMENT OR PRESERVATION THEREOF
LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
27Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
30Artificial sweetening agents
 Appl.No 19335292 Applicant CARGILL, INCORPORATED Inventor Dan S. Gaspard

A solubilized steviol glycoside composition including one or more steviol glycosides and one or more steviol glycoside solubility enhancers can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) such as foods, beverages, medicines, oral hygiene compositions, pharmaceuticals, nutraceuticals, and the like.

5.20260015379Enzymatic RNA Capping Method
US - 15.01.2026
Int.Class C07H 19/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
 Appl.No 19306143 Applicant New England Biolabs, Inc. Inventor G. Brett Robb

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

6.20260014184ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER
US - 15.01.2026
Int.Class A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
 Appl.No 19139661 Applicant UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED Inventor Youcef MEHELLOU

The invention relates to a compound of General Formula (I): (General Formula I) wherein R1 and R2 are as defined herein: for use in the treatment of neurodegenerative diseases or conditions that are characterised by an elevated level of Ubiquitin Ser65 phosphorylation and/or in the treatment of cancer. The invention also relates to pharmaceutical compositions and combination therapeutic agents comprising compounds of formula (I) for treating these conditions as well to a method of treating such diseases and conditions using the compounds of General Formula (I).

7.WO/2026/015080LINKAGE GROUPS, OLIGONUCLEOTIDE CONJUGATES, AND METHODS THEREOF
WO - 15.01.2026
Int.Class C07H 9/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
9Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
02the hetero ring containing only oxygen as ring hetero atoms
04Cyclic acetals
 Appl.No PCT/SG2025/050460 Applicant AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Inventor YING, Jackie Yi-ru
This disclosure concerns linkage groups and uses thereof for conjugating ligands to nucleic acids. Also provided are oligonucleotide-ligand conjugates containing the linkage group, and uses thereof for targeted nucleic acid delivery and as a medicament.
8.20260015377CRYSTALLINE FORM I OF REDUCED NICOTINAMIDE MONONUCLEOTIDE DISODIUM MONOHYDRATE AND PREPARATION METHOD THEREFOR
US - 15.01.2026
Int.Class C07H 19/048
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
048Pyridine radicals
 Appl.No 19095548 Applicant Greenanew (Shanghai) Biotech Co., Ltd. Inventor Yantao QI

The invention relates to a crystalline form I of the reduced nicotinamide mononucleotide disodium monohydrate (NMNH) as shown in formula I, and its preparation method. The crystalline form I exhibits X-ray powder diffraction peaks at 2θ angles of 10.502°±0.2°, 12.721°±0.2°, 20.036°±0.2°, and 21.633°±0.2° using CuKα radiation. This crystalline form I has advantages such as good stability, low hygroscopicity, ease of storage, and a simple preparation method, making it suitable for large-scale production.

embedded image

9.20260015595ENGINEERED GLYCOSYLTRANSFERASES AND STEVIOL GLYCOSIDE GLUCOSYLATION METHODS
US - 15.01.2026
Int.Class C12N 9/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
 Appl.No 19330442 Applicant Tate & Lyle Solutions USA LLC Inventor Jonathan VROOM

The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to make products with β-glucose linkages. The present invention further provides compositions and methods for the production of rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising the SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.

10.20260015376CONTINUOUS FLOW METHODS FOR PRODUCING MANNOSE-1-PHOSPHATE, POLYMORPHS OF MANNOSE-1-PHOSPHATE, AND COMPOSITIONS AND USES RELATED THERETO
US - 15.01.2026
Int.Class C07H 11/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
11Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
04Phosphates; Phosphites; Polyphosphates
 Appl.No 18866947 Applicant Glycomine, Inc. Inventor Geoffrey S. HIRD

Provided herein are methods of synthesizing and compositions comprising an alpha isomer of mannose-1-phosphate (M1P). For example, such methods employ techniques in flow chemistry to achieve a substantially pure alpha isomer of M1P. Also provided are compositions, including pharmaceutical compositions, comprising substantially pure alpha isomer of M1P. Provided herein are also polymorphic forms of M1P, including polymorphic forms that may be produced from the substantially pure alpha isomer of M1P.

# -